6 days agoAnavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Nov 25Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Oct 31Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
May 9Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Nov 24, 2023Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Oct 25, 2023Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of
Sep 14, 2023Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Jun 20, 2023Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 1, 2023ANAVEX Announces New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
May 2, 2023Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Apr 25, 2023Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 2, 2022Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
